Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Trifluridine/Tipiracil

It is intended for the treatment of adult patients with metastatic colorectal cancer
02 Mar 2016
Gastrointestinal cancers;  Anticancer agents & Biologic therapy

On 25 February 2016, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product trifluridine/tipiracil (Lonsurf), intended for the treatment of adult patients with metastatic colorectal cancer.

The applicant for this medicinal product is Les Laboratoires Servier.

Lonsurf will be available as film-coated tablets (15 mg / 6.14 mg and 20 mg / 8.19 mg).

It is an antineoplastic agent combined with a thymidine phosphorylase inhibitor (ATC code: L01BC59). The active substances are trifluridine and tipiracil. Trifluridine is phosphorylated by thymidine kinase, further metabolised in cells to a deoxyribonucleic acid (DNA) substrate, and incorporated directly into DNA, thereby interfering with DNA function and preventing cell proliferation. The role of tipiracil is to inhibit the degradation of trifluridine by thymidine phosphorylase.

When added to best supportive care (BSC) Lonsurf improved survival compared to BSC alone.

The most common side effects are neutropenia, nausea, fatigue, anaemia and leucopenia.

The full indication is:

"Lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents".

It is proposed that Lonsurf be prescribed by physicians experienced in the administration of anticancer therapy.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Last update: 02 Mar 2016

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings